These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20685117)

  • 21. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M; Chiarella J; Kozal MJ
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
    AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.
    Nguyen TT; Rato S; Molina JM; Clavel F; Delaugerre C; Mammano F
    J Antimicrob Chemother; 2015 Mar; 70(3):731-8. PubMed ID: 25336162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
    Smith RA; Raugi DN; Pan C; Coyne M; Hernandez A; Church B; Parker K; Mullins JI; Sow PS; Gottlieb GS;
    PLoS One; 2012; 7(9):e45372. PubMed ID: 23028968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
    Zhao XZ; Maddali K; Metifiot M; Smith SJ; Vu BC; Marchand C; Hughes SH; Pommier Y; Burke TR
    Chem Biol Drug Des; 2012 Feb; 79(2):157-65. PubMed ID: 22107736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
    Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
    Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
    Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.
    Delelis O; Malet I; Na L; Tchertanov L; Calvez V; Marcelin AG; Subra F; Deprez E; Mouscadet JF
    Nucleic Acids Res; 2009 Mar; 37(4):1193-201. PubMed ID: 19129221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
    Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
    J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MK-0536 inhibits HIV-1 integrases resistant to raltegravir.
    Métifiot M; Johnson B; Smith S; Zhao XZ; Marchand C; Burke T; Hughes S; Pommier Y
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5127-33. PubMed ID: 21876054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of Elvitegravir-resistance HIV-1 integrase.
    Chen Q; Cheng X; Wei D; Xu Q
    Interdiscip Sci; 2015 Mar; 7(1):36-42. PubMed ID: 25519157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors.
    Patel M; Naidu BN; Dicker I; Higley H; Lin Z; Terry B; Protack T; Krystal M; Jenkins S; Parker D; Panja C; Rampulla R; Mathur A; Meanwell NA; Walker MA
    Bioorg Med Chem; 2020 Jul; 28(13):115541. PubMed ID: 32389483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors.
    Wai JS; Kim B; Fisher TE; Zhuang L; Embrey MW; Williams PD; Staas DD; Culberson C; Lyle TA; Vacca JP; Hazuda DJ; Felock PJ; Schleif WA; Gabryelski LJ; Jin L; Chen IW; Ellis JD; Mallai R; Young SD
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5595-9. PubMed ID: 17822898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.
    Kobayashi M; Nakahara K; Seki T; Miki S; Kawauchi S; Suyama A; Wakasa-Morimoto C; Kodama M; Endoh T; Oosugi E; Matsushita Y; Murai H; Fujishita T; Yoshinaga T; Garvey E; Foster S; Underwood M; Johns B; Sato A; Fujiwara T
    Antiviral Res; 2008 Nov; 80(2):213-22. PubMed ID: 18625269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.
    Hare S; Vos AM; Clayton RF; Thuring JW; Cummings MD; Cherepanov P
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20057-62. PubMed ID: 21030679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors.
    Dayam R; Sanchez T; Clement O; Shoemaker R; Sei S; Neamati N
    J Med Chem; 2005 Jan; 48(1):111-20. PubMed ID: 15634005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
    King PJ; Ma G; Miao W; Jia Q; McDougall BR; Reinecke MG; Cornell C; Kuan J; Kim TR; Robinson WE
    J Med Chem; 1999 Feb; 42(3):497-509. PubMed ID: 9986720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
    Kertesz DJ; Brotherton-Pleiss C; Yang M; Wang Z; Lin X; Qiu Z; Hirschfeld DR; Gleason S; Mirzadegan T; Dunten PW; Harris SF; Villaseñor AG; Hang JQ; Heilek GM; Klumpp K
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4215-8. PubMed ID: 20538456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.